The therapeutic potential of laquinimod for Huntington’s disease: A systematic review of preclinical and clinical studies
Preclinical evidence suggests laquinimod may modulate motor, inflammatory, and myelination pathways in HD; however, clinical evidence shows no meaningful benefit. Data on long-term safety remain limited. Larger, well-designed trials using standardized biomarkers are needed to clarify its therapeutic potential.
Authors
- Dina Hemmati
- Hesam Mosavari (ORCID: https://orcid.org/0000-0001-9701-8490)
- Tara Khoeini (ORCID: https://orcid.org/0000-0002-6351-6499)
- Mehri Salari (ORCID: https://orcid.org/0000-0002-1675-681X)
- Esther Cubo
- Mohammad Rohani
- Negin Eissazade
Institutions
- Iran University of Medical Sciences (IR)
- Institute for Cognitive Science Studies (IR)
- Hospital Universitario de Burgos (ES)
- Institut des Sciences Cognitives (FR)
- Universidad de Burgos (ES)
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- Neurodegenerative Disease Management
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1080/17582024.2026.2637425
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00